Boston Scientific's WATCHMAN FLX Pro trial meets primary endpoints
BSX•Boston Scientific reported positive six-month primary results from the SIMPLAAFY trial of its WATCHMAN FLX Pro device. Aspirin alone and reduced-dose anticoagulants matched dual antiplatelet therapy for stroke protection with less bleeding; reduced-dose anticoagulants also showed fewer device-related blood clots.
1. Six-month trial results
Boston Scientific said aspirin alone and reduced-dose anticoagulant regimens matched dual antiplatelet therapy for stroke protection in the SIMPLAAFY trial, with less bleeding. The reduced-dose anticoagulant regimen also showed fewer device-related blood clots. Results were presented at Transcatheter Cardiovascular Therapeutics 2026 and published in JAMA.
